Search company, investor...
Search

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
betterlabs.net

See what CB Insights has to offer

Investments

13

Partners & Customers

6

About Better

Better is a product incubation firm that incubates products for early stage startup founders. It works closely with founders to turn their ideas into a working 1.0 version that can be tested and validated with real users. The firm is completely invested in the success of the product with a cash and equity -based engagement model.

Better Headquarters Location

1600 Duane Ave

Santa Clara, California, 95054,

United States

408-223-1075

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Better Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Better Rank

Research containing Better

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Better in 5 CB Insights research briefs, most recently on Jul 19, 2022.

Latest Better News

Outlook on the Cell Therapy Global Market to 2028 - Increased Demand for Novel, Better Medicines for Diseases Such as Cancer and CVD Has Resulted in an Increase in General Research Efforts

Oct 5, 2022

The Global Cell Therapy Market was valued at USD 14.86 Billion in 2021, and it is expected to reach a value of USD 35.95 Billion by 2028, at a CAGR of 13.45% over the forecast period (2022 - 2028). The cell therapy industry is being propelled forward by an increase in the number of clinical trials for cell-based treatments. As a result, global investment in research and clinical translation has increased significantly. The increasing number of ongoing clinical studies can be attributed to the presence of government and commercial funding bodies that are constantly providing funds to assist projects at various stages of clinical trials. Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Segments covered in this report The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region. Based on Use-type it is categorized into Clinical-use, and Research-use. Based on Therapy Type it is categorized into Allogenic Therapies, Autologous Therapies. Based on Product it is categorized into Consumables, Equipment, Systems, and Software. Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA. Drivers The increased demand for novel, better medicines for diseases such as cancer and CVD has resulted in an increase in general research efforts as well as funding for cell-based research. In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia. The project would receive a USD 102 million (AU$150 million) grant from the Medical Research Future Fund (MRFF) to encourage stem cell research in order to develop novel medicines. Similarly, the UK's innovation agency, Innovate the UK, awarded USD 269,670 (GBP 267,000) in funding in September 2019 to Atelerix's gel stabilization technologies, with the first goal of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature. Restraints Despite technological advancements and product development over the last decade, the industry has been hampered by a lack of skilled personnel to operate complex devices like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are both technologically advanced and extremely complex, generate a wide range of data outputs that require skill to analyze and review. There is a global demand-supply mismatch for competent individuals, according to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS). Over the next decade, the UK and Europe are expected to face a severe shortage of lab capabilities, with medical laboratories being particularly hard hit. Market Trends The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC). It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells. Key Topics Covered: COVID Strategies By Company Political Impact Market segments Market segments Market segments Market segments Data Table on Market share by geography 2021-2028(%) North America Data Table on Market share by country 2021-2028(%) USA Data Table on Market share by country 2021-2028(%) Germany Data Table on Market share by country 2021-2028(%) China Data Table on Market share by country 2021-2028(%) Brazil Data Table on Market share by country 2021-2028(%) GCC Countries Top companies market positioning Merck KGaA (Germany) Lonza Group (Switzerland) Avantor, Inc. (US)

Better Investments

13 Investments

Better has made 13 investments. Their latest investment was in CUSMAT as part of their Seed VC on September 9, 2021.

CBI Logo

Better Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/30/2021

Seed VC

CUSMAT

$0.1M

Yes

6

11/18/2019

Seed VC

Kaarva

Yes

3

Other Investors

Jovian.ml

Yes

Other Investors

Subscribe to see more

Subscribe to see more

0

Other Investors

Subscribe to see more

Subscribe to see more

0

Date

9/30/2021

11/18/2019

Round

Seed VC

Seed VC

Other Investors

Other Investors

Other Investors

Company

CUSMAT

Kaarva

Jovian.ml

Subscribe to see more

Subscribe to see more

Amount

$0.1M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

3

0

0

Better Partners & Customers

6 Partners and customers

Better has 6 strategic partners and customers. Better recently partnered with Palantir Technologies on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/17/2022

Partner

United States

Peter Thiel’s Palantir Teams Up With Better to Create ‘Bloomberg’ for Home Loans - VICE

The partnership will allow the mortgage company , Better , to quickly create a beefed-up mortgage platform that CEO Vishal Garg described to Insider as `` Bloomberg for loans . ''

1

6/21/2022

Partner

Finland

Subscribe to see more

Subscribe to see more

10

2/28/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

7/16/2021

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

7/10/2021

Client

United States

Subscribe to see more

Subscribe to see more

10

Date

8/17/2022

6/21/2022

2/28/2022

7/16/2021

7/10/2021

Type

Partner

Partner

Partner

Partner

Client

Business Partner

Country

United States

Finland

United States

Switzerland

United States

News Snippet

Peter Thiel’s Palantir Teams Up With Better to Create ‘Bloomberg’ for Home Loans - VICE

The partnership will allow the mortgage company , Better , to quickly create a beefed-up mortgage platform that CEO Vishal Garg described to Insider as `` Bloomberg for loans . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.